Vitrolife Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St

April 03, 2025

Vitrolife (STO:VITR) Full Year 2024 Results

Key Financial Results

Revenue: kr3.61b (up 2.8% from FY 2023).
Net income: kr513.0m (up from kr3.85b loss in FY 2023).
Profit margin: 14% (up from net loss in FY 2023). The move to profitability was primarily driven by lower expenses.
EPS: kr3.79 (up from kr28.44 loss in FY 2023).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

revenue-and-expenses-breakdown — OM:VITR Revenue and Expenses Breakdown April 3rd 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Vitrolife EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 3.7%.

The primary driver behind last 12 months revenue was the Genetics segment contributing a total revenue of kr1.50b (41% of total revenue). The largest operating expense was Sales & Marketing costs, amounting to kr754.0m (46% of total expenses). Explore how VITR's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 7.6% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Sweden.

Performance of the Swedish Biotechs industry.

The company's share price is broadly unchanged from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. See our latest analysis on Vitrolife's balance sheet health.

If you're looking to trade Vitrolife, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.